Public health officials in the United Kingdom have identified a fresh, recombinant form of mpox in a traveler recently returned from Asia, raising concerns about the evolving nature of the virus and potential challenges for future prevention efforts. This discovery, announced on February 14, 2026, marks the first documented case of this specific viral combination and underscores the need for continued global surveillance of mpox.
Mpox, formerly known as monkeypox, is a viral infection related to the smallpox virus. Initial symptoms often mimic those of the flu – fever, headache, muscle aches, and backache – followed by swollen lymph nodes and exhaustion. Within a few days, a characteristic rash or sores can develop, typically starting on the face and spreading to other parts of the body. Transmission occurs through close contact with these sores, fluids from the sores, or contaminated materials like clothing and bedding. The virus can also spread via respiratory secretions, making close, prolonged contact – including kissing – a potential route of infection.
Understanding the Two Main Clades of Mpox
Researchers have identified two primary clades, or genetic branches, of the mpox virus currently circulating globally: Clade IIb and Clade Ib. Each presents different levels of risk and transmission patterns.
Clade IIb: The 2022 Global Outbreak
Clade IIb was responsible for the widespread mpox outbreak in 2022, infecting approximately 114,000 people and causing 220 deaths worldwide. In the United States, cases peaked in the summer of 2022, reaching 11,000 cases per month. This clade is generally considered less severe, causing mild symptoms in most individuals and carrying a mortality rate of around 1%. During the 2022 outbreak, transmission was primarily observed through sexual contact among men who have sex with men, though it is not exclusively spread this way.
Clade Ib: A More Severe Strain
Clade Ib, in contrast, is associated with more serious illness and a significantly higher fatality rate of approximately 10%. This variant has been present in the Democratic Republic of Congo (DRC) for many years, traditionally spreading from animals to humans through activities like butchering and consuming bushmeat. While, a new outbreak that began in the DRC in 2023 has demonstrated person-to-person transmission. In some regions of Africa, Clade Ib is spreading within families through everyday household activities and in healthcare settings where adequate protective equipment is lacking. Notably, this clade has also been linked to sexual transmission, particularly among sex workers and transient populations like truck drivers.
Between January and November 2025, over 48,000 cases of Clade Ib mpox were reported in Central and Eastern Africa. Approximately 43 cases were identified in other countries, with roughly half linked to recent travel to Africa and the remaining 24 occurring in individuals with no known travel history. The World Health Organization (WHO) now believes Clade Ib is spreading locally in several countries, including Italy, Malaysia, the Netherlands, Portugal, Spain, and the United States.
A Recombinant Virus: Combining Clade IIb and Clade Ib
Genomic testing revealed that the patient in England is infected with a recombinant virus, meaning it contains genetic material from both Clade IIb and Clade Ib. This recombination is a natural process that can occur when two related viruses infect the same individual, exchanging genetic information and creating a new viral strain. Experts emphasize that viral evolution is expected, given the concurrent circulation of both clades.
The discovery of this recombinant strain raises concerns about potential challenges in controlling the spread of mpox. Dr. Boghuma Titanji, assistant professor of medicine at Emory University, told the BBC, “The more mpox circulation we permit, the more opportunities the virus has to recombine and adapt, further entrenching mpox virus as a human pathogen that is not going away.”
Vaccination Remains a Key Defense
The JYNNEOS vaccine offers protection against both mpox and smallpox. Administered in two doses, four weeks apart, vaccination reduces the risk of infection and can lessen the severity of symptoms if infection occurs.
The Centers for Disease Control and Prevention (CDC) recommends the mpox vaccine for gay, bisexual, transgender, or other men who have sex with men who have had (in the last six months) or expect to have one or more sexually transmitted infections, more than one sexual partner, anonymous sexual or intimate contact, sex at a commercial sex venue, or sex in association with a large public event in a geographic area where mpox transmission is occurring. This targeted vaccination campaign played a crucial role in curbing the spread of mpox in the United States in 2022.
Individuals who meet these criteria and have not yet been vaccinated are urged to do so as soon as possible. While the new recombinant strain has not yet been detected in the United States, both Clade IIb and Clade Ib continue to circulate at low levels.
The WHO’s public health risk assessment for mpox remains unchanged: moderate for men who have sex with men with new or multiple partners and for sex workers or others with multiple casual sexual partners, and low for the general population without specific risk factors.
Public health officials continue to monitor the situation closely, and further updates will be provided as more information becomes available. The emergence of this recombinant virus highlights the importance of ongoing surveillance, vaccination efforts, and public awareness campaigns to mitigate the spread of mpox.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share this information with your network and join the conversation below.
Worth a look
